- Home
- ETR vs MRNA Comparison
ETR vs MRNA Comparison
Compare ETR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETR | MRNA |
|---|---|---|
| Founded | 1949 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6B | 61.6B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ETR | MRNA |
|---|---|---|
| Price | $104.44 | $224.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 23 |
| Target Price | $121.18 | ★ $122.67 |
| AVG Volume (30 Days) | 2.7M | ★ 13.9M |
| Earning Date | 11-02-2026 | 11-06-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 59.59 | 21.77 |
| EPS | ★ 0.83 | N/A |
| Revenue | $12,946,686,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $7.98 | $8.09 |
| Revenue Next Year | $9.45 | $16.07 |
| P/E Ratio | $126.49 | ★ N/A |
| Revenue Growth | ★ 8.98 | 4.29 |
| 52 Week Low | $90.87 | $22.28 |
| 52 Week High | $118.45 | $227.46 |
Technical Indicators
Market Signals| Indicator | ETR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 70.65 |
| Support Level | $104.42 | $45.39 |
| Resistance Level | $107.26 | N/A |
| Average True Range (ATR) | 1.69 | 13.87 |
| MACD | 0.78 | 0.53 |
| Stochastic Oscillator | 93.81 | 92.06 |
Price Performance
Historical ComparisonAbout ETR Entergy Corporation
Entergy is a holding company with five regulated vertically integrated utilities that generate and distribute electricity to 3 million customers in Arkansas, Louisiana, Mississippi, and Texas. It is one of the largest power producers in the country with 27 gigawatts of rate-regulated owned and leased power generation capacity. Entergy was the second-largest nuclear owner in the US before it began retiring and selling its plants in the Northeast in 2014. It sold its two small gas utilities in Louisiana in 2025.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.